Massachusetts Center for Birth Defects Research and Prevention

马萨诸塞州出生缺陷研究与预防中心

• 批准号: 8610037
• 负责人: Marlene Anderka
• 金额: $ 35万
• 依托单位: MASSACHUSETTS STATE DEPT OF PUB HEALTH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8610037
• 关键词: Massachusetts; Center; Birth; Defects; Research

Project Summary / Abstract The Massachusetts (MA) Center for Birth Defects Research and Prevention (MCBDRP) proposes to continue its strong track record of conducting etiologic research to identify modifiable risk factors for structural birth defects through its participation in the Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS). We will enhance our contributions by leveraging our already established training program designed to produce future birth defects researchers. MCBDRP brings to BD-STEPS our expertise and leadership in pharmacoepidemiology and collaborative utilization of unique data resources to be applied to all four key areas named in the Funding Opportunity Announcement. Our research will utilize existing data from the National Birth Defects Prevention Study, data to be collected as part of BD-STEPS and data sets unique to our collaborative team including the Pregnancy to Early Life Longitudinal database, the MA Outcomes Study of Assisted Reproductive Technologies, the Slone Epidemiology Center's multi-site Birth Defects Study, and the North American Antiepileptic Drug Pregnancy Registry. MCBDRP investigators are committed and successful mentors and collaborative partners, roles that will continue and expand within BD-STEPS. Over the five year grant period, the MCBDRP will complete at least 10 etiologic research projects that cover medically significant and common exposures as they relate to risks of birth defects including: 1) Oral diabetic medications, more common as the prevalence of diabetes increases; 2) Anti-obesity medications, which given the current increase in obesity have been and will continue to be approved by FDA; 3) Medications and procedures to treat infertility, an area where MA offers unique strengths due to the large number of older mothers and high utilization of assisted reproductive technology (ART); 4) Medications that contain the endocrine-disruptor phthalates, which will be a model for proposing to study additional inactive ingredients in medications; 5) Antiepileptic medications including the study of genetic factors which increase the risk for birth defects; 6) Non- steroidal anti-inflammatory drugs, important because they are used by more than 20% of pregnant women; 7) Drugs for nausea and vomiting of pregnancy, key because of the increasing use of some medications for this pregnancy-specific condition; 8) Spatio-temporal clustering of birth defects, an indication of environmental or infectious etiology, including an expansion of our work on gastroschisis and extension of the research methodology to other birth defects; 9) Antidepressants, specifically selective serotonin reuptake inhibitors, including effect modifiers and genetically determined predictors related to specific agents; and 10) Medications taken during pregnancy, including over-the-counter products, and through a periodic screening of BD-STEPS data, identifying new products that may pose a risk. Through these activities, MCBDRP will be an essential partner in BD-STEPS to achieve our overall goal of translating research findings into meaningful prevention initiatives.

项目总结/摘要 马萨诸塞州（MA）出生缺陷研究和预防中心（MCBDRP）建议继续 它在进行病因学研究以确定结构性分娩的可改变风险因素方面的良好记录 通过参与出生缺陷研究来评估妊娠缺陷（BD-STEPS）。我们 我们将通过利用我们已经建立的培训计划来加强我们的贡献， 未来的出生缺陷研究者MCBDRP为BD-STEPS带来了我们的专业知识和领导力， 药物流行病学和协作利用独特的数据资源，应用于所有四个关键领域 在融资机会公告中。我们的研究将利用现有的数据，从国家 出生缺陷预防研究，作为BD-STEPS的一部分收集的数据以及我们独有的数据集 合作团队，包括妊娠至早期生命纵向数据库，MA结局研究， 辅助生殖技术，斯隆流行病学中心的多点出生缺陷研究， 北美抗癫痫药物妊娠登记处。MCBDRP调查人员致力于并取得成功 导师和合作伙伴，将在BD-STEPS中继续和扩大的角色。五年来 在拨款期间，MCBDRP将完成至少10个病因学研究项目，包括医学上重要的 与出生缺陷风险相关的常见暴露包括：1）口服糖尿病药物， 常见的糖尿病的患病率增加; 2）抗肥胖药物，鉴于目前 肥胖症增加已经并将继续得到FDA的批准; 3）药物和程序， 治疗不孕症，这是MA提供独特优势的一个领域，因为大量的高龄母亲和高 使用辅助生殖技术（ART）; 4）含有内分泌干扰物的药物 邻苯二甲酸酯，这将是一个模型，建议研究药物中的其他非活性成分; 5） 抗癫痫药物，包括研究增加出生缺陷风险的遗传因素; 6）非 甾体抗炎药，重要的是因为它们被20%以上的孕妇使用; 7） 妊娠恶心和呕吐的药物，关键是因为越来越多的药物用于此 8）出生缺陷的时空聚集，环境或 感染性病因学，包括我们对腹裂的工作扩展和研究的扩展 9）抗抑郁药，特别是选择性5-羟色胺再摄取抑制剂， 包括与特定药剂相关的效应调节剂和遗传决定的预测因子;以及10）药物 在怀孕期间服用，包括非处方药，并通过BD-STEPS的定期筛查 数据，识别可能构成风险的新产品。通过这些活动，小额信贷、复员和重返社会方案将成为一个重要的 BD-STEPS的合作伙伴，以实现我们将研究成果转化为有意义的预防的总体目标 举措